Očovská Zuzana, Maříková Martina, Kočí Jaromír, Vlček Jiří
Department of Social and Clinical Pharmacy, Faculty of Pharmacy in Hradec Králové, Charles University, Hradec Králové, Czechia.
Department of Clinical Pharmacy, Hospital Pharmacy, University Hospital Hradec Králové, Hradec Králové, Czechia.
Front Pharmacol. 2022 Jun 13;13:899151. doi: 10.3389/fphar.2022.899151. eCollection 2022.
Drug-related hospital admissions (DRAs) represent a significant problem affecting all countries worldwide. This study aimed to determine the prevalence and preventability of DRAs, identify the most common medications involved in DRAs, the most common clinical manifestations of DRAs and describe the preventability aspects of DRAs. This cross-sectional study examined unplanned hospital admissions to the University Hospital Hradec Králové the department of emergency medicine in August-November 2018. Data were obtained from electronic medical records. The methodology of DRA identification was adapted from the OPERAM DRA adjudication guide. Out of 1252 hospital admissions, 195 DRAs have been identified (145 related to treatment safety, 50 related to treatment effectiveness). The prevalence of DRAs was 15.6% (95% CI 13.6-17.6). The most common medication classes involved in DRAs related to treatment safety were Antithrombotic agents, Antineoplastic agents, Diuretics, Corticosteroids for systemic use, and Beta blocking agents. The most common medication classes involved in DRAs related to treatment effectiveness included Diuretics, Antithrombotic agents, Drugs used in diabetes, Agents acting on the renin-angiotensin system, and Lipid modifying agents. Gastrointestinal disorders were the leading causes of DRAs related to treatment safety, while Cardiac disorders were the leading causes of DRAs related to treatment effectiveness. The potential preventability of DRAs was 51%. The highest share of potential preventability in medication classes repeatedly involved in DRAs related to treatment safety was observed for Anti-inflammatory and antirheumatic products, Psycholeptics, and Drugs used in diabetes. Potentially preventable DRAs related to treatment safety were most commonly associated with inappropriate drug selection, inappropriate monitoring, inappropriate dose selection, and inappropriate lifestyle measures. On the contrary, DRAs related to treatment effectiveness were more commonly associated with medication nonadherence. It should be emphasized that in most DRAs, medications were only a contributory reason of hospital admissions and that benefits and risks have to be carefully balanced. It is highlighted by the finding that the same medication classes (Antithrombotic agents and Diuretics) were among the most common medication classes involved in DRAs related to treatment safety and simultaneously in DRAs related to treatment effectiveness. The study highlighted that apart from problems related to prescribing, problems related to monitoring and patient-related problems represent significant preventability aspects.
与药物相关的住院(DRAs)是一个影响全球所有国家的重大问题。本研究旨在确定DRAs的患病率和可预防性,识别DRAs中最常见的药物、DRAs最常见的临床表现,并描述DRAs的可预防方面。这项横断面研究调查了2018年8月至11月在赫拉德茨克拉洛韦大学医院急诊科的非计划住院情况。数据从电子病历中获取。DRA识别方法改编自OPERAM DRA判定指南。在1252例住院病例中,已识别出195例DRAs(145例与治疗安全性相关,50例与治疗有效性相关)。DRAs的患病率为15.6%(95%CI 13.6 - 17.6)。与治疗安全性相关的DRAs中最常见的药物类别是抗血栓药物、抗肿瘤药物、利尿剂、全身用皮质类固醇和β受体阻滞剂。与治疗有效性相关的DRAs中最常见的药物类别包括利尿剂、抗血栓药物、糖尿病用药、作用于肾素 - 血管紧张素系统的药物和调脂药物。胃肠道疾病是与治疗安全性相关的DRAs的主要原因,而心脏疾病是与治疗有效性相关的DRAs的主要原因。DRAs的潜在可预防性为51%。在与治疗安全性相关的DRAs中反复涉及的药物类别中,抗炎和抗风湿产品、抗精神病药物以及糖尿病用药的潜在可预防性占比最高。与治疗安全性相关的潜在可预防DRAs最常与药物选择不当、监测不当、剂量选择不当和生活方式措施不当有关。相反,与治疗有效性相关的DRAs更常与用药依从性差有关。应该强调的是,在大多数DRAs中,药物只是住院的一个促成因素,必须仔细权衡益处和风险。同一药物类别(抗血栓药物和利尿剂)同时出现在与治疗安全性相关的DRAs和与治疗有效性相关的DRAs中最常见的药物类别中,这一发现突出了这一点。该研究强调,除了与处方相关的问题外,与监测相关的问题和与患者相关的问题也是重要的可预防方面。